Project Grant R01AT013631
Award Date 8/15/26
Completion Date 7/31/29
Dollars Obligated $2.1M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Emigration Canyon, UT 84108, USA
Similar Awards
- The National Institute on Drug Abuse awarded the University of Utah $162,200 on October 10, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize pain embodiment and its relationship to opioid misuse risk in chronic pain using neuroimaging. The award funds a five-year research project through September 30, 2030, performed in Salt Lake City, Utah. The research will employ resting-state functional magnetic resonance imaging to study pain embodiment—the tendency...
- The National Institute on Drug Abuse awarded the University of Utah $107,188 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a retrospective analysis of telehealth prescribing patterns and veteran health outcomes related to opioid and stimulant use disorders. The recipient will evaluate opioid- and stimulant-related morbidity and mortality among veterans who received prescriptions through the Veterans Health Administration between 2020 and 2025....
- Summary The University of Washington received a $4.45M Cooperative Agreement from the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279) effective August 1, 2025 through July 31, 2028. The project adapts and implements a Nurse Care Management (NCM) model designed to address chronic pain in rural populations through an evidence-based, multi-component intervention. The NCM model integrates care coordination, cognitive behavioral...
- The National Institute on Drug Abuse awarded the University of Utah $1,442,744 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the Co-Use of Opioids and Alcohol Prevention Study (COAPS) 2.0. The award funds a hybrid type-2 implementation effectiveness study designed to scale an alcohol-targeted brief intervention-medication therapy management (ABI-MTM) intervention across community pharmacy settings. The study will execute a three-pronged...
- The National Institute of Neurological Disorders and Stroke awarded The Ohio State University $10.115 million on September 12, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a prospective observational study modeling diverse experiences and longitudinal trajectories of acute pain in emergency department settings. The study—titled MODEL-PAIN (MOdeling Diverse Experiences and Longitudinal trajectories of pain)—will enroll 2,400 emergency department patients and...
- The National Institute of General Medical Sciences awarded the University of Utah $454,300 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate genetic and neural circuit mechanisms underlying the acute-to-chronic pain transition in chronic postsurgical pain. The research employs three consomic rat strains—SS-5BN, SS-6BN, and SS-13BN—that develop persistent pain-like behaviors following hind paw incision to test whether recruitment of...
- The National Institute of Neurological Disorders and Stroke awarded the University of Tennessee $475,375 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and pilot a family-based pain intervention for Appalachian breast cancer patients experiencing treatment-related pain during adjuvant endocrine therapy. The Conquering Pain Together (CPT) intervention addresses pain discontinuation as a primary driver of therapy non-adherence in rural Appalachia,...
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health under the Department of Health and Human Services, awarded the University of Maryland, Baltimore $4.929 million on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a multi-omic, psychosocial, and environmental model of individual differences in pain and placebo responses. The project investigates chronic pain conditions, particularly...
- Federal Cooperative Agreement Summary: Equitable Primary Care for Pain Care (EquiP PC) The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Washington a $1,024,374 Cooperative Agreement on August 11, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test implementation strategies for integrating behavioral health into primary care for chronic pain management. The project, titled Equitable Primary Care for Pain Care...
- The National Institute of Neurological Disorders and Stroke awarded Yale University $4.17 million on August 25, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a biopsychosocial model for peripheral artery disease pain management that integrates vascular interventions with psychological and behavioral assessment. The project develops novel MRI protocols to evaluate blood flow, muscle and nerve microstructure, and metabolism in patients with peripheral artery...